EUVIMEDEUVIMED entdecken
Crossref

A pharmacovigilance study of association between proton‐pump inhibitors and rhabdomyolysis event based on FAERS database

Yuxuan Sun, Ailin Zhang, Meiling Zuo, Jingtao Chen, Liqin Zhu iD

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Yuxuan Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical College, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Rhabdomyolysis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim The association between proton‐pump inhibitors (PPIs) and rhabdomyolysis were unclear. The aim of this study was to explore and systematically analyze the potential link between five PPIs and the rhabdomyolysis events using the FDA Adverse Event Reporting System (FAERS) database.

Methods

Suspected rhabdomyolysis events associated with PPIs were identified by data mining with the reporting odds ratio (ROR), proportional reporting ratio (PRR), the information component (IC), and Empirical Bayes Geometric Mean (EBGM). Demographic information, drug administration, and outcomes of PPI‐induced rhabdomyolysis events were also analyzed.

Results

There were 3311 reports associated with PPI‐induced rhabdomyolysis that were identified. After removing duplicates, 1899 cases were determined to contain complete patient demographic data. The average age was 65 ± 18 year and 57% were male. Omeprazole and pantoprazole had the same largest percentage of reports. Lansoprazole had the highest ROR index of 12.67, followed by esomeprazole (11.18), omeprazole (10.27), rabeprazole (10.06), and pantoprazole (9.24). PRR, IC, and EBGM showed similar patterns. This suggested that lansoprazole exhibited the strongest correlation with rhabdomyolysis. In rhabdomyolysis events, PPIs were mainly “concomitant” (>60%), and only a few cases were “primary suspects” (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsRhabdomyolysisMaleHumansMiddle AgedAgedAged, 80 and overFemalePantoprazoleRabeprazolePharmacovigilanceBayes TheoremOmeprazoleLansoprazole

Stichwörter der Autor:innen

Adverse drug eventsDrug safetyPharmacovigilanceProton-pump inhibitorsRhabdomyolysis

Substanzen

Proton Pump InhibitorsPantoprazoleRabeprazoleOmeprazoleLansoprazole

Autor:innen und Institutionen

  • Pharmaceutical College, Tianjin Medical University, Tianjin, China.
  • School of Statistics and Data Science, Nankai University, Tianjin, China.
  • Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China.

ORCID-Profile: Liqin Zhu

Zitieren

APA

Sun, Y., Zhang, A., Zuo, M., Chen, J., & Zhu, L. (2024). A pharmacovigilance study of association between proton‐pump inhibitors and rhabdomyolysis event based on FAERS database. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16411

Vancouver

Sun Y, Zhang A, Zuo M, Chen J, Zhu L. A pharmacovigilance study of association between proton‐pump inhibitors and rhabdomyolysis event based on FAERS database. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16411

BibTeX
@article{Sun2024,
  author = {Sun, Yuxuan and Zhang, Ailin and Zuo, Meiling and Chen, Jingtao and Zhu, Liqin},
  title = {A pharmacovigilance study of association between proton‐pump inhibitors and rhabdomyolysis event based on FAERS database},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16411}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche